President Donald Trump’s recent executive orders imposing tariffs on imported goods are expected to significantly increase costs within the U.S. healthcare industry and disrupt supply chains, according to industry analysts.
The tariffs, which include a 10% minimum tariff and broader reciprocal tariffs, are projected to raise the price of medical supplies, pharmaceuticals, and medical devices. An analysis cited by Fierce Healthcare suggests tariffs on Canadian-made drugs alone could add $750 million in costs. Hospitals and clinics may face increased expenses for essential equipment, potentially impacting budgets and patient care quality.
Experts predict that hospitals could see operating income levels drop without cost savings or other revenue sources, according to Healthcare Dive.
The tariffs also threaten to disrupt the availability of medical supplies and equipment, potentially leading to shortages or delays. Manufacturers may seek suppliers outside of Canada and Mexico, potentially leading to supply shortages. The complex global nature of pharmaceutical supply chains means tariffs could cause significant disruptions.
Specific sectors expected to be affected include pharmaceuticals, where prescription drug prices could increase and potential shortages of essential medications could occur; medical devices, where tariffs could lead to increased costs and potential shortages; and personal protective equipment, where costs for items like gloves and masks could increase.
Economists predict the tariffs could lead to increased inflation and slowed economic growth, potentially reducing funding for public health programs.
Healthcare organizations and industry groups are lobbying for exemptions, particularly for medical devices and pharmaceuticals. Some are considering diversifying suppliers and proactively negotiating with existing ones to mitigate the impact.
